Exelixis, Inc. (ticker: EXEL, exchange: NASDAQ Global Market (.O))
News Release -
Reminder: Exelixis Announces December 12 Webcast of Its Fourth AnnualR&D Day
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Dec. 8, 2008--Exelixis, Inc. (Nasdaq:EXEL) announced today that it will hold its
Fourth Annual R&D Day on Friday, December 12, 2008 from 10:00 a.m. EST /
7:00 a.m. PST to 2:00 p.m. EST / 11:00 a.m. PST in New York. Exelixis
management will discuss the company's corporate strategy, financial
outlook and development pipeline.
The event will be webcast and may be accessed in the Event Calendar page
under Investors at http://www.exelixis.com.
An archive of this webcast will be available until 9:00 p.m. PST/12:00
a.m. EST on January 12, 2009. Access numbers for this replay are:
1-888-286-8010 (domestic) and 1-617-801-6888 (international); the replay
passcode number is: 90996892.
Exelixis, Inc. is a development-stage biotechnology company dedicated to
the discovery and development of novel small molecule therapeutics for
the treatment of cancer and other serious diseases. The company is
leveraging its fully integrated drug discovery platform to fuel the
growth of its development pipeline, which is primarily focused on
cancer. Currently, Exelixis' broad product pipeline includes
investigational compounds in phase 3, phase 2, and phase 1 clinical
development. Exelixis has established strategic corporate alliances with
major pharmaceutical and biotechnology companies, including
GlaxoSmithKline, Bristol-Myers Squibb, Genentech, Wyeth Pharmaceuticals,
and Daiichi-Sankyo. For more information, please visit the company's web
site at www.exelixis.com.
Exelixis and the Exelixis logo are registered U.S. trademarks.
CONTACT: Exelixis, Inc.
Charles Butler, 650-837-7277 (Investors)
Soleil Maxwell Harrison, 650-837-7012 (Media)
Source: Exelixis, Inc.